Breaking News

Chi-Med’s Surufatinib Study Meets Primary Endpoint Early

Stops Phase III study of surufatinib in advanced neuroendocrine tumors, meeting the primary endpoint of progression free survival

Hutchison China MediTech Ltd. announced that the independent Data Monitoring Committee (IDMC) of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic (SANET-ep) has completed a planned interim analysis. The IDMC determined that the study has already met the pre-defined primary endpoint of progression free survival (PFS) and as a result the study will be stopped. Chi-Med will now arrange for a pre-New Drug Application (NDA) meeting with the China National Med...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters